Oculis Holding AG entered into an asset purchase agreement with Accure Therapeutics S.L. to acquire worldwide development and commercial rights to Privosegtor (ACT-01) and the early-stage candidate ACT-02. The transaction involves a $3.8 million upfront cash payment and the issuance of up to 2,050,000 Oculis ordinary shares subject to lockup release or milestone vesting. This acquisition terminates Oculis' existing license agreement with Accure, eliminating associated milestone payments and royalties while securing global commercial rights. The closing for Privosegtor is expected by February 28, 2027, contingent on the ACT-01 transaction, with ACT-02 closing expected by March 31, 2027. Oculis Holding AG operates in the biopharmaceutical industry, focusing on neuro-ophthalmology and ophthalmology treatments.

Oculis Holding AG reported unaudited financial results for the six months ended June 30, 2026. The company incurred a net loss of CHF 38.8 million ($49.3 million), compared to CHF 58.6 million in the prior year period. Operating expenses totaled CHF 45.8 million, with research and development costs at CHF 29.3 million and general and administrative expenses at CHF 16.5 million. The improved loss performance was primarily driven by a CHF 4.1 million fair value gain on warrant liabilities and favorable foreign currency exchange gains of CHF 1.8 million. Cash, cash equivalents, and short-term investments stood at CHF 228.3 million ($282.3 million) as of June 30, 2026, providing a runway into the second half of 2029. The company continues to advance its neuro-ophthalmology pipeline, including the PIONEER program for Privosegtor and the PREDICT-1 trial for Licaminlimab.